Lung Volume Reduction Followed by Lung Transplantation in Emphysema — A Multicenter Matched Analysis

Alexis Slama1,2†, Laurens J. Ceulemans3,4†, Celia Hedderich1, Panja M. Boehm5, Jan Van Slambrouck3,4, Stefan Schwarz5, Christelle M. Vandervelde3, Markus Kamler3, Peter Jaksch5, Dirk Van Raemdonck3,4, Konrad Hoetzenecker5 and Clemens Aigner1,2†

1Department of Thoracic Surgery and Thoracic Endoscopy, University Medicine Essen, Ruhrlandklinik, Essen, Germany, 2West German Center for Lung Transplantation, University Medicine Essen, Essen, Germany, 3Department of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium, 4Department of Chronic Diseases and Metabolism, Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), KU Leuven, Leuven, Belgium, 5Clinic of Thoracic Surgery, Medical University of Vienna, Vienna, Austria

Objective: The impact of previous lung volume reduction surgery (LVRS) or endoscopic lung volume reduction (ELVR) on lung transplantation (LuTX) remains unclear. This study assesses the risk of previous lung volume reduction on the outcome of a later LuTX.

Methods: Patients suffering from emphysema who underwent bilateral LuTX were included in this multicenter analysis. Study groups were defined as: previous LVRS, previous ELVR, controls. Imbalances were corrected by coarsened exact matching for center, gender, age, diagnosis, and BMI. A comparative analysis of intraoperative characteristics, perioperative outcome and long-term survival was performed.

Results: 615 patients were included (LVRS = 26; ELVR = 60). Compared to controls, LVRS patients had a higher rate of postoperative ECMO (15.4 vs. 3.9%; \( p = 0.006 \)), whereas ELVR patients suffered more often from wound infections (8.9% vs. 2.5%; \( p = 0.018 \)). Perioperative outcome, duration of ventilation, ICU stay, and hospital stay were comparable between groups. Bacterial colonization of the airway differed significantly between both LVR groups and controls in pre- and post-LuTX cultures. Survival was not impacted (1-/3-/5-year survival for LVRS: 92.3%/85.7%/77.1%; controls: 91.3%/82.4%/76.3%; \( p = 0.58 \) | ELVR: 93.1%/91%/91%; controls 91.2%/81.7%/75.3%; \( p = 0.17 \)).

Conclusion: Lung volume reduction does not impact short and long-time survival after bilateral LuTX. Due to differences in airway colonization after LVR, caution to prevent infectious complications is warranted.

Keywords: ELVR, emphysema, LVRS, lung transplantation, lung volume reduction

Abbreviations: BMI, body mass index; CEM, coarsened exact matching; CLAD, chronic lung allograft dysfunction; COPD, chronic obstructive pulmonary disease; CPB, cardio pulmonary bypass; CVA, cerebro-vascular accident; ECMO, extracorporeal membrane oxygenation; ECS, extra corporeal support; ELVR, endoscopic lung volume reduction; ICU, intensive care unit; LAS, lung allocation score; LuTX, lung transplantation; LVR, lung volume reduction; LVRS, lung volume reduction surgery; MOF, multi-organ failure; 6MWT, six minutes walking test; PGD, primary graft dysfunction; QOL, quality of life; VATS, video assisted thoracic surgery.
INTRODUCTION

Patients with end-stage pulmonary emphysema have limited therapeutic options. Lung volume reduction (LVR) and lung transplantation (LuTX) have been shown to improve lung function, quality of life (QOL) and survival, despite an associated perioperative risk (1, 2). Lung volume reduction surgery (LVRS) has gained popularity in the nineties, however, remained undervalued and underused after the large NETT trial (3–5). In more recent years, endoscopic lung volume reduction (ELVR) techniques by implantation of valves or coils, thermal ablation, or instillation of chemical sealants emerged (6). However, the effect of all LVR procedures is counteracted by the progression of disease usually leading to a decay in lung function after several months to years following treatment, leaving LuTX as the last option (7). Due to the protracted clinical course of COPD in comparison to other end-stage lung diseases, the best timing for LuTX referral remains debated. Guidelines for LuTX selection recommend the use of the BODE score, which is a good predictor for pre-LuTX mortality and post-LuTX survival benefit (8).

With increased use of LVR in highly impaired “low FEV1” patients (9, 10), and the more apparent overlap of patients eligible for both LVR and LuTX, the use of LVR procedures as a “bridge to transplant” has gained acceptance (7).

Simultaneous referral of patients for both LVR and LuTX is always recommended, and the decision should be taken in an interdisciplinary emphysema board with access to all treatment options (8). Those therapies are not mutually exclusive, and most combinations have been reported, of which, in most cases, LuTX was considered the last resort when all other previous therapies failed.

In a previous review, twelve published reports on LVRS and one on ELVR preceding LuTX were identified (11). North American papers showed that LVRS before LuTX can negatively affect survival (12, 13). Other publications demonstrated only an increased perioperative risk with no impact on survival (14–16). Nevertheless, these conclusions were not supported by the most recent and largest single institution report, in which no adverse effect of a previous LVRS was observed (17).

The increased surgical risk after LVRS can potentially be attributed to a higher occurrence of adhesions and thereby a longer operation time, more bleeding complications, and a higher need for blood transfusions. Also, a higher risk of injury to the phrenic nerve during adhesiolysis has been hypothesized but was never confirmed in the available reports (11).

For ELVR prior to LuTX, available data is even more scarce, with only a single institutional analysis available (18). In 20 ELVR patients, outcome was comparable to a matched control group, although ELVR was associated with a higher occurrence of bacterial airway colonization. This observation has been recently confirmed in a larger cohort outside the scope of LuTX (19).

Given the rarity and controversy of available evidence on the impact of LVRS and ELVR on a later lung transplantation, this study aimed to further determine the short- and long-term outcomes in these patients.

METHODS

We conducted a multicenter retrospective analysis of post-LuTX outcomes in patients suffering from emphysema. Data was collected and anonymized before transmission between...
participating centers. This study was approved by the ethics committee of the Medical Faculty of the University of Duisburg-Essen (21-9856-BO).

**Study Population**
Data was collected from three European high volume LVR and LuTX centers (Essen, Leuven, Vienna). All patients who underwent a bilateral LuTX for COPD or α-1 antitrypsin deficiency were included. The timespan for inclusion was defined individually for each center ranging from their first patient undergoing LuTX after previous LVR according to recent treatment algorithms (Essen: 2/2015; Vienna: 1/2015, Leuven: 1/2010) until August 2020. Patients with re-LuTX, unilateral LuTX or preoperative ECMO support were excluded from the analysis.

**Recipient Characteristics**
Variables routinely used for listing, lung allocation score (=LAS) calculation, and organ allocation (dependent on center-specific approaches) were collected and used for analysis: age, waiting time, pack years, functional parameters, supplemental oxygen need, and pulmonary arterial pressure. LAS-data was only available for two centers. Intra-operative data included the need for size reduction (wedge or lobar LuTX), intraoperative cardiopulmonary support (ECMO, no support, CPB), duration of surgery, and cold ischemic time of both lungs independently.

**Endpoints**
The primary endpoint was 1-year survival after LuTX. Secondary endpoints included duration of mechanical ventilation, time to discharge from ICU and from hospital. Surgical and medical complications were categorized and the need for postoperative ECMO was assessed. Data collection allowed for the entry of two causes of death and survival was compared to unmatched unweighted data.

**Bacterial Samples**
An additional secondary endpoint of the study was to assess potential differences in airway and bronchial colonization. All positive cultures of the respiratory tract obtained while waiting for LuTX were recorded. Sputum cultures, bronchoalveolar lavage samples and swabs of the explanted recipient lung were considered. In one center, the information for every sample taken after transplantation could also be included and was used for a subgroup analysis.

**Matching**
A matching algorithm was applied to reduce imbalance between groups of treated patients and controls, and to thereby improve the estimation of causal effects by statistical testing. For this purpose, “coarsened exact matching” (=CEM) was used (20). CEM has the capacity to approximate a fully blocked randomized trial unlike propensity score matching (PSM), being a less data efficient and more biased completely randomized approach (21). Coarsening was achieved by considering 5 covariates: center, gender, diagnosis, age, and BMI. LAS was not included variables as it is dependent on three of the five included variables (age, diagnosis and BMI).

**Statistics**
Preprocessing of data to generate matched groups was carried out by means of R (R-Foundation for Statistical Computing, Vienna, Austria), SPSS (IBM Corp., Armonk, NY) and CEM-Extension bundle (Matthew Blackwell). All statistical analyses were conducted with SPSS v.25. Variables were assumed to be non-parametric and are reported as median and range and compared by Mann-Whitney-U tests. Nominal data were compared by means of chi-squared test. Cases in the control groups were weighted by the CEM algorithm and frequency weight data values were rounded to the nearest integers if needed by analysis or in tables. Patient survival between the groups was compared by log-rank (Mantel-cox) tests on unmatched groups and unweighted matched data. Two-sided P values <0.05 were considered statistically significant. No adjustment for multiple testing was used.

**RESULTS**
615 patients [320 (52%) female and 295 (48%) male] were included in this study. Of those, 26 (4.2%) underwent LVRS before LuTX and 60 (9.8%) had ELVR prior to transplantation. Mean age was 58 ± 5.9 years. Indications for LuTX were COPD in 572 (93%) cases and alpha-1 antitrypsin deficiency emphysema in 43 (7%) cases. In 24 (92.3%) LVRS patients, surgery took place before listing (5.8 ± 1.6 years; range: 5.0–8.4) whereas in two cases (7.7%), LVRS was performed while patients were on the waitlist for LuTX (2.2 and 4.4 years after listing). Median time from LVRS to LuTX was 4.0 (1.1–32.7) years. LVRS was either unilateral (15; 58%) or bilateral (11; 42%). Surgical access for LVRS was VATS in 11 (44%) cases and open surgery via thoracotomy or sternotomy in 14 (56%) cases. In one patient this information was missing. Most LVRS were performed by parenchymal stapling (n = 22; 85%). The remaining 4 patients underwent lobectomy (15%).

Out of 60 patients with previous ELVR, 54 (90%) had the intervention before being listed for LuTX (5.8 years; range: 5.0–6.0) and 6 (10%) on the waiting list (5.8 ± 2.5 years; range: 4.0–6.8 after listing). Time from ELVR to LuTX was 2.7 (0.02–7.4) years. 50 (83.3%) patients had unilateral interventions and 10 (16.7%) bilateral. The procedures were: valves: 50 (83.3%), coils: 9 (15%) and a combination of both in 1 (1.7%) case. One of the patients treated with valves had hydrogel foam instilled in the contralateral apical lobe. In 20 out of 51 (39%) patients with valves, later re-intervention became necessary to either reposition or remove the valves because of unsuccessful treatment.

All 26 patients with a history of LVRS (TLVRS) were matched to 328 weighted controls (CtLVRS). In patients with ELVR, 56 patients (TetLVRS) remained in the analysis (n = 4 unmatched by lack of partners) and 270 weighted controls (CtetLVRS). Metrics on matching are presented in the supplementary file (Table 1).

Pre-LuTX characteristics of treatment groups and matched controls are presented in Table 1. After coarsened exact matching, groups were balanced throughout demographic variables. Patients undergoing LuTX after previous LVRS had a lower median LAS at time of LuTX (32.4 vs. 33.4; p = 0.038) and lesser need for oxygen (2 vs. 3 L/min; p = 0.033; however, this was not considered of clinical relevance.
14.5% of all allocated grafts were size reduced during LuTX to match the recipient chest. Size reduction was performed either by wedge resection (n = 83; 13.5%) or by lobar transplantation (n = 6; 1.0%). 44.3% of patients had intraoperative extra corporeal support (ECS), either by ECMO (42.7%) or to a lesser extent by means of cardiopulmonary bypass (1.6%). The use of size reduction or ECS was comparable between groups. More detailed intraoperative data of both treatment groups and their weighted controls are presented in Table 2.

Verify that all the equations and special characters are displayed correctly. In patients with previous LVRS (T_LVRS) duration of LuTX (348 vs. 323 min; p = 0.296), as well as total ischemic time (TIT) of both donor lungs (465 vs. 403 min; p = 0.101) was statistically comparable to controls. Patients with previous ELVR did not exhibit significant differences in transplant duration and ischemic times, compared to their matched controls (283 vs. 288 min; p = 0.703 and 360 vs. 380 min; p = 0.180).

Short-term perioperative results (reoperation rates, intubation duration, time on ICU and time in hospital) were excellent throughout treatment groups (T_LVRS and T_ELVR). When compared to controls no clinically relevant differences were

### TABLE 1 | Demographics and patient characteristics ahead of LuTX.

|                  | T_LVRS (n = 26) | C_LVRS (n = 328) | p =  | T_ELVR (n = 56) | C_ELVR (n = 270) | p =  |
|------------------|----------------|-----------------|-----|----------------|-----------------|-----|
| Gender           |                |                 |     |                |                 |     |
| Female           | 13 (60.0%)     | 50.0%           | 1.000 | 29 (51.8%)     | 51.8%           | 0.988 |
| Male             | 13 (60.0%)     | 50.0%           |     | 27 (48.2%)     | 48.2%           |     |
| Diagnosis        |                |                 |     |                |                 |     |
| α-1-AT def.      | 2 (7.7%)       | 7.7%            | 0.990 | 3 (5.4%)       | 5.4%            | 0.963 |
| COPD             | 24 (92.3%)     | 92.3%           |     | 53 (94.6%)     | 94.6%           |     |
| Age at LuTX (y)  | 59 (42–70)     | 57 (45–74)      | 0.649 | 66 (45–72)     | 58 (42–74)      | 0.946 |
| BMI              | 31.8 (29.9–33.8) | 32.9 (31.1–35.1) | 0.033 | 32.8 (30.6–35.1) | 30.9 (27.8–33.3) | 0.038 |
| 6MWT (m)         | 21.1 (18.5–27.6) | 22.5 (16.2–29.7) | 0.101 | 22.5 (16.0–30.9) | 21.6 (12.6–31.7) | 0.184 |
| rTLC (L)         | 56 (43–70)     | 57 (45–74)      |     | 66 (45–72)     | 58 (42–74)      |     |
| pTLC (L)         | 6.25 (4.38–7.9) | 5.83 (3.65–8.2) | 0.948 | 5.83 (3.83–7.86) | 5.71 (3.98–8.67) | 0.782 |
| FEV1 (%)         | 21 (9.9–66)    | 19.6 (10–94)    | 0.088 | 19.1 (10–41)   | 19.9 (9.9–85)   | 0.338 |
| PAP mmHg         | 32 (21–59)     | 32 (8–94)       | 0.191 | 34 (18–70)     | 31 (8–94)       | 0.368 |
| LAS at listing   | 31.8 (29.9–35.1) | 32.9 (27.8–69.7) | 0.076 | 32.0 (29.6–38.5) | 32.8 (27.8–69.7) | 0.185 |
| LAS at LuTX      | 32.4 (29.9–40.9) | 33.4 (27.8–87.2) | 0.038 | 33.5 (25.6–90.2) | 33.0 (27.8–87.2) | 0.223 |
| O2 Therapy (L/min) | 2 (0–6)       | 3 (0–15)        | 0.033 | 2 (0–8)       | 2 (0–15)        | 0.696 |
| pre-LuTX hospitalization | No | 25 (96.2%) | 89.9% | 0.306 | 50 (89.3%) | 92.5% | 0.435 |
| Yes             | 1 (3.8%)       | 10.1%           |     | 6 (10.7%)      | 7.5%            |     |
| pre-LuTX MV     | No             | 19 (73.1%)      | 69.2% | 0.680 | 41 (73.2%) | 62.7% | 0.297 |
| Noninvasive ET intubation | 7 (26.9%) | 30.8% |     | 15 (26.8%) | 36.4% | 0.9% |
|                     |                |                 |     |                |                 |     |
### TABLE 2 | Intra-operative characteristics of LuTX.

|                  | T_LVRS (n = 26) | C_LVRS (n = 328) | p =  | T_ELVR (n = 56) | C_ELVR (n = 270) | p =  |
|------------------|----------------|-----------------|-----|----------------|-----------------|-----|
| Size reduction of the graft |                |                 |     |                |                 |     |
| No               | 19 (73.1%)     | 78.4%           | 0.532 | 41 (73.2%)     | 74.9%           | 0.802 |
| Yes             | 7 (26.9%)      | 21.6%           |     | 15 (26.8%)     | 25.1%           |     |
| Which size reduction |                |                 |     |                |                 |     |
| Wedge unilat.    | 2 (7.7%)       | 7.3%            | 0.785 | 2 (3.6%)       | 7.4%            | 0.512 |
| Wedge. bilat.    | 5 (19.2%)      | 14.2%           |     | 13 (22.2%)     | 15.9%           |     |
| Lobe unilat.     | 0.1%           |                 |     | 0.680          | 1.2%            |     |
| Lobe bilat.      |                |                 |     |                |                 |     |
| Intra-OP ECS     |                |                 |     |                |                 |     |
| None             | 9 (36.0%)      | 33.5%           | 0.069 | 12 (21.4%)     | 18.1%           | 0.747 |
| CPB             | 2 (7.7%)       | 5.7%            |     | 1 (1.8%)       | 2.4%            |     |
| vaECMO          | 15 (60.0%)     | 60.4%           |     | 43 (76.8%)     | 77.9%           |     |
| vvECMO          | 1 (4.0%)       | 0.3%            |     |                | 1.5%            |     |
| LuTX duration (min) | 348 (137–705) | 323 (150–743)   | 0.296 | 283 (150–460)  | 288 (137–705)   | 0.703 |
| TIT 1st implanted side (min) | 295 (173–577) | 293 (158–812)   | 0.816 | 285 (175–542)  | 299 (158–698)   | 0.051 |
| TIT 2nd implanted side (min) | 465 (218–639) | 403 (235–960)   | 0.101 | 360 (235–692)  | 380 (218–769)   | 0.180 |

Data expressed as median (range) or counts (%); control columns include weighted data; significant p-values are bold; TLVRS, patients with previous LVRS; C_LVRS, matched controls; TELVR, patients with previous ELVR; C_ELVR, matched controls; a-1-AT def., alpha-1 antitrypsin deficiency emphysema; BMI, body mass index; 6MWT, 6-min walking test; rTLC, measured total lung capacity; pTLC, predicted total lung capacity; FEV1, forced expiration volume; PAP, pulmonary arterial pressure; LAS, lung allocation score; MV, mechanical ventilation; ET, endotracheal.

Numbers are median (range) or counts (%); control columns include weighted data; significant p-values are bold; TLVRS, patients with previous LVRS; C_LVRS, matched controls; T_ELVR, patients with previous ELVR; C_ELVR, matched controls; TELVR, matched controls; COPB, cardio-pulmonary bypass; vaECMO, veno-arterial extracorporeal membrane oxygenation; vvECMO, veno-venous ECMO; TIT, total ischemic time of the graft. Significant p-values are highlighted in bold italic.
observed (Table 3). Nevertheless, in patients with previous LVRS a significantly higher rate of post-LuTX ECMO use was recorded (15.4% vs. 3.8%; \( p = 0.006 \)).

In TLVRS complications occurred in 8 (30.8%) and in TELVR in 13 (23.2%) patients. Slight differences in the spectrum of complications were identified as LVRS patients had a higher

### Table 3 | Post-LuTX Outcomes

|                          | TLVRS \((n = 26)\) | CLVRS \((n = 328)\) | \( p = \) | TELVR \((n = 56)\) | CELVR \((n = 270)\) | \( p = \) |
|--------------------------|---------------------|---------------------|-----------|---------------------|---------------------|-----------|
| Surgical revision        | 5 (19.2%)           | 17.7%               | 0.843     | 8 (14.3%)           | 16.2%               | 0.708     |
| Successful weaning       | 24 (96.0%)          | 95.5%               | 0.894     | 24 (98.2%)          | 98.3%               | 0.973     |
| Days ventilated          | 2 (0.5–23)          | 2 (0.5–79)          | 0.159     | 2 (0.5–19)          | 2 (0.5–79)          | 0.563     |
| Post-OP ECMO             | 4 (15.4%)           | 3.6%                | 0.006     | 1 (1.6%)            | 6.4%                | 0.179     |
| Post-OP ECMO (days)      | 7 (3–39)            | 4 (2–10)            | 0.078     | 2 (2–2)             | 5 (2–10)            | 0.250     |
| Days on ICU              | 7 (3–213)           | 6 (2–152)           | 0.149     | 6 (2–107)           | 7 (2–152)           | 0.127     |
| Days to transfer to normal ward | 11 (5–213) | 10 (3–118) | 0.154     | 9 (2–107)           | 9 (2–118)           | 0.382     |
| Days to dismissal from hospital | 35 (15–105) | 37 (9–152) | 0.717     | 42 (18–109)         | 35 (8–152)          | 0.158     |
| Death before dismissal   | 2 (7.7%)            | 8.0%                | 0.963     | 1 (1.8%)            | 5.8%                | 0.203     |

Control columns consist of weighted data; TLVRS, patients with previous LVRS; CLVRS, matched controls; TELVR, patients with previous ELVR; CELVR, matched controls; surgical revisions include all later surgical interventions on the chest and the lungs; ICU, intensive care unit. Significant \( p \) values are highlighted in bold italic.

### Table 4 | Post-LuTX Complications and Causes of Death

|                          | TLVRS \((n = 26; t: n = 6)\) | CLVRS \((n = 328; t: n = 70*)\) | \( p = \) | TELVR \((n = 56; t: n = 6)\) | CELVR \((n = 270; t: n = 62)*\) | \( p = \) |
|--------------------------|-----------------------------|-------------------------------|-----------|-----------------------------|-------------------------------|-----------|
| Complications            |                             |                               | 0.754     |                             |                               | 0.444     |
| Pleural effusion         | 1 (3.8%)                    | 10.1%                         |           | 1 (1.8%)                    | 6.8%                          |           |
| Empyema/lung abscess     | 2 (7.7%)                    | 1.2%                          | 0.014     | 3 (5.4%)                    | 3.1%                          |           |
| Pneumothorax/air leak    | 3 (11.5%)                   | 6.7%                          |           | 4 (7.1%)                    | 6.5%                          |           |
| Pneumonia                | 2.3%                        |                               |           | 1.8%                        |                               |           |
| Pneumonic nerve injury/diaph. palsy | 1.2% |                               |           | 2.5%                        |                               |           |
| Wound                    | 1 (3.8%)                    | 2.7%                          |           | 5 (8.9%)                    | 2.5%                          |           |
| Abdominal                | 2 (7.7%)                    | 4.8%                          |           | 3 (5.4%)                    | 4.6%                          |           |
| Arrhythmia               | 1 (3.8%)                    | 2.5%                          |           | 1 (1.8%)                    | 1.1%                          |           |
| ECMO related             | 1.1%                        |                               |           | 1.8%                        |                               |           |
| Chest wall               | 1.2%                        |                               |           | 1.6%                        |                               |           |
| Sepsis                   | 0.8%                        |                               |           | 1.8%                        |                               |           |
| PGO 3                    | 3 (11.5%)                   | 8.3%                          |           | 2.9%                        |                               |           |
| Thrombosis/embolism      | 1 (3.8%)                    | 0.8%                          |           | 1.3%                        |                               |           |
| Renal failure            | 3.6%                        |                               |           | 1.6%                        |                               |           |

Causes of death

|                          | TLVRS \((n = 26; t: n = 6)\) | CLVRS \((n = 328; t: n = 70*)\) | \( p = \) | TELVR \((n = 56; t: n = 6)\) | CELVR \((n = 270; t: n = 62)*\) | \( p = \) |
|--------------------------|-----------------------------|-------------------------------|-----------|-----------------------------|-------------------------------|-----------|
| Unknown                  | 1 (16.7%)                   | 26.9%                         | 0.881     | 1 (16.7%)                   | 14.1%                         | 0.031     |
| Sepsis                   | 1 (16.7%)                   | 13.0%                         |           | 25.0%                       |                               |           |
| Pneumonia                | 2 (33.3%)                   | 18.2%                         |           | 11.1%                       |                               |           |
| MOF                      | 1 (16.7%)                   | 7.3%                          |           | 24.1%                       |                               |           |
| GI bleeding/ischemia     | 1 (16.7%)                   | 3.3%                          |           | 10.6%                       |                               |           |
| Resp. insufficiency      | 1 (16.7%)                   | 10.2%                         |           | 25.9%                       |                               |           |
| Bleeding                 | 2.4%                        |                               |           | 6.4%                        |                               |           |
| Graft failure            | 1 (16.7%)                   | 1.9%                          | 0.044     | 1 (16.7%)                   | 1.5%                          | 0.034     |
| Kidney failure           | 1.9%                        |                               |           | 3.9%                        |                               |           |
| Malignancy               | 1.9%                        |                               |           | 2.2%                        |                               |           |
| Cardiac arrest/failure   | 3.9%                        |                               |           | 6.9%                        |                               |           |
| CLAD                     | 14.5%                       | 1 (16.7%)                     |           | 5.0%                        |                               |           |
| Acute/humoral rejection  | 6.0%                        |                               |           | 3.6%                        |                               |           |
| Pulmonary embolism       | 1.9%                        |                               |           |                               |                               |           |
| Euthanasia               | 0.3%                        |                               |           |                               |                               |           |
| ECMO-failure             | 1.5%                        | 1 (16.7%)                     |           | 0.2%                        |                               |           |
| Ischemic CVA             | 2.1%                        |                               |           |                               |                               |           |
| Myelopathy               | 0.3%                        |                               |           |                               |                               |           |

Multiple answers were allowed; complications are expressed as percentage of whole group, causes of death in relation of total deaths; TLVRS, patients with previous LVRS; CLVRS, matched controls; TELVR, patients with previous ELVR; CELVR, matched controls; surgical revisions include all later surgical interventions on the chest and the lungs; ICU, intensive care unit. Significant \( p \) values are highlighted in bold italic.
occurrence of post-operative empyema (n = 2; 7.7% vs. 1.2%; p = 0.014). On the other hand, ELVR patients had a higher rate of wound infections (n = 5; 8.9% vs. 2.5%; p = 0.018). In deceased patients, graft failure was reported more often as cause of death in both treatment groups compared to controls (LVRS: 16.7% vs. 1.9%; p = 0.044 | ELVR: 16.7% vs. 1.5%; p = 0.034). All recorded complications and causes of death are presented in Table 4.

In patients with previous LVR treatment, microbiologic colonization or infection was more often detected and the spectrum of positive cultures differed significantly (LVRS: 42.3% vs. 31.1%; p = 0.009 | ELVR: 39.3% vs. 32.4%; p = 0.01) as shown in Table 5. After LuTX and immunosuppression, the rate of positive cultures increased (LVRS: 54.5% vs. 72.8%; p = 0.005 | ELVR: 76.9% vs. 76.8%; p = 0.021) and as expected certain species became more prevalent as the microbiome changed (enterococcus spp., yeasts, mycobacteria, aspergillus; Table 6).

Short and long-term survival after LuTX was excellent across groups and controls and consistently comparable with the control groups (1-/5-year: LVRS: 92.3%/77.1%/p = 0.583|ELVR: 98.3%/91.0%/p = 0.174). Median survival after LuTX was: LVRS: 9.95 years and ELVR: 7.56 years. Median survival for controls was not calculated as more than 50% of those patients were still alive at time of analysis (Figure 1).

**DISCUSSION**

This multi-center matched retrospective cohort study, assessed post-operative outcomes of emphysema patients, who underwent surgical or endoscopic LVR prior to LuTX. After matching, baseline indicators

---

**TABLE 5 | Microbiological colonization before LuTX.**

| Colonization pre-LuTX | TLVRS (n = 26) | CLVRS (n = 328) | p (%) | TELVR (n = 56) | CELVR (n = 270) | p (%) |
|-----------------------|---------------|----------------|-------|---------------|----------------|-------|
| None                  | 15 (57.7%)    | 68.9           | 0.009 | 34 (60.7%)    | 67.6           | 0.010 |
| Candida sp. or YLF    | 8 (30.8%)     | 13.7           |       | 14 (25.0%)    | 16.8           |       |
| Aspergillus spp.      | 1 (3.8%)      | 7.5            |       | 4 (7.1%)      | 1.7            | 0.022 |
| Pseudomonas spp.      |               | 6.8            |       | 1 (1.8%)      | 5.2            |       |
| Staphylococcus aureus | 1 (3.8%)      | 5.7            |       | 4 (7.1%)      | 3.2            |       |
| Klebsiella spp.       | 1 (3.8%)      | 4.0            |       | 3 (5.4%)      | 2.1            |       |
| Escherichia coli      | 1 (3.8%)      | 1.8            |       | 2 (3.6%)      | 5.1            |       |
| Serratia marcescens   | 1 (3.8%)      | 3.1            |       | 2 (3.6%)      | 3.9            |       |
| Stenotrophomonas maltophilia | 1 (3.8%) | 1.4 |       | 1 (1.8%)      | 4.9            |       |
| Pasteurella multocida | 1 (3.8%)      |               |       | 1 (1.8%)      |               |       |
| Achromobacter spp.    | 1 (3.8%)      | 0.7            |       |               | 0.9            |       |
| Enterobacter cloacae complex | 1 (3.8%) | 0.4 |       |               | 3.0            |       |
| Streptococcus spp.    | 1 (3.8%)      | 0.3            |       | 0.027         | 4.3            |       |
| Slow growing NTM      | 2.6           |               |       |               | 1 (1.8%)       | 1.9   |

Species with occurrence <3% in all groups were omitted from table; control columns consist of weighted data; TLVRS, patients with previous LVRS; CLVRS, matched controls; TELVR, patients with previous ELVR; CELVR, matched controls; YLF, yeast like fungi; NTM, nontuberculous mycobacteria. Significant p values are highlighted in bold italic.

**TABLE 6 | Microbiological cultures after LuTX in one center.**

| Colonization post-LuTX | TLVRS (n = 11) | CLVRS (n = 138) | p (%) | TELVR (n = 26) | CELVR (n = 126) | p (%) |
|------------------------|---------------|----------------|-------|---------------|----------------|-------|
| None                   | 5 (45.5%)     | 27.2           | 0.005 | 6 (23.1%)     | 32.2           |       |
| Enterococcus spp.      | 5 (45.5%)     | 51.5           |       | 13 (60.0%)    | 32.3           |       |
| Slow growing NTM       | 3 (27.3%)     | 2.5            |       | 3 (11.5%)     | 5.1            |       |
| Candida spp. or YLF    | 3 (27.3%)     | 43.0           |       | 14 (63.8%)    | 41.3           |       |
| Aspergillus species    | 2 (18.2%)     | 14.5           |       | 7 (26.9%)     | 28.5           |       |
| Staphylococcus epidermidis | 1 (9.1%) | 2 (7.7%)       |       |               |               |       |
| Enterobacter cloacae complex | 2.5 | 3 (11.5%) | 3.3 |
| Stenotrophomonas maltophilia | 9.3 | 2 (7.7%) | 11.1 |
| Escherichia coli       | 4.2           | 1 (3.8%)       |       | 1 (3.8%)      | 9.8            |       |
| Klebsiella spp.        | 2.5           |               |       | 1 (3.8%)      |               |       |
| Achromobacter spp.     | 3.4           |               |       | 2.6           |               |       |
| Staphylococcus aureus  | 3.2           |               |       | 7.8           |               |       |
| Citrobacter freundii   | 0.8           |               |       | 3.3           |               |       |
| Rapid growing NTM      | 0.8           |               |       | 3.3           |               |       |
| Pseudomonas spp.       | 10.3          |               |       | 18.2          |               |       |

Percentages <3% in all groups were omitted; control columns consist of weighted data; TLVRS, patients with previous LVRS; CLVRS, matched controls; TELVR, patients with previous ELVR; CELVR, matched controls; NTM, nontuberculous mycobacteria; YLF, yeast like fungi. Significant p values are highlighted in bold italic.
and intraoperative modalities were comparable between groups and controls. The analysis showed that both previous LVRS and ELVR were associated with a different spectrum of bacterial colonization prior to LuTX which must be considered to prevent infectious complications. LVR did not impact short- and long-term survival, which was equally good in all groups.

Interestingly we observed that patients with previous LVRS had a higher rate of post-operative ECMO need after LuTX. This might be explained by a longer and more difficult preparation due to pleural adhesions. Hence, potentially leading to longer surgery durations/ischemic times and an increased need for blood transfusions, all known risk factors for early mortality and PGD (22–24). Three cases of PGD 3 within 72 h occurred in the LVRS group. In previous publications, an association of previous LVRS with a higher pulmonary arterial pressure and an increased risk of phrenic nerve palsy was postulated (13, 15). These assumptions are not corroborated by our data as median PAP was 32 mmHg and not a single case of phrenic nerve injury was observed in the LVRS group. Additionally, it is noteworthy that in this cohort, the outcome in LVRS patients was statistically comparable to the outcome in patients with previous non-LVRS intrathoracic surgery.

To the best of our knowledge, this study is the largest published series about ELVR prior to LuTX. Those patients had equally good perioperative outcomes as controls although a higher occurrence of wound infections (8.9% vs. 2.5%; \( p = 0.018 \)) was observed. Out of those five patients, four had positive sputum cultures (Candida/Aspergillus/Klebsiella) before LuTX. After LuTX, these patients suffered also from empyema \( n = 3 \) and pneumonia \( n = 1 \). Although the association between ELVR and post-LuTX wound infection is not fully understood, we hypothesize that a different spectrum of pre-transplant colonization and an increased exposure to antibiotics might make them more susceptible to hospital acquired infections and multi-drug resistant bacteria.

This study is the first to assess extensively airway colonization of LuTX recipients who underwent previous LVRS or ELVR. It showed that LVR was associated with a distinct airway microbiome both before and after LuTX. In comparison to other LuTX-indications COPD has a lower risk of bacterial infections (25). It was unexpected that the number of colonized patients were as high even before LuTX (LVRS: 42.3%; ELVR: 39.3%). Unfortunately, data on colonization after LuTX was only available for one of the three participating centers. In this subgroup, colonization rates of 54% in LVRS patients and 76.9% in ELVR patients were seen after LuTX.

In LVRS patients a higher rate of slow growing mycobacteria was observed after LuTX in comparison to the control group (27.3% vs. 2.5%; \( p < 0.001 \)), an observation which cannot be readily explained. On the other hand, ELVR has been previously associated with pathological colonization as implanted valves and coils impede mucus clearance (26). Although a predominance of \textit{Stenotrophomonas maltophilia} (40%) after ELVR and LuTX has been described (18), this relationship could not be confirmed by our data in which only 7.7% patients presented with \textit{s.maltophilia} after LuTX.

The strength of this study and its conclusion is given by its design. Three high volume centers experienced in both LVR and LuTX provided data on all patients recently transplanted for emphysema at their institution. To correct for selection bias and differences in patient characteristics, LVRS and ELVR patients were matched to weighted control groups. This led to highly balanced groups.

The observations of this study are mostly in line with a recent single-center analysis comparing 52 LVRS+LuTX patients to 65 unmatched controls (17). However, our findings differed markedly from those of a recent UNOS-database analysis (12) which included 106 LVRS+LuTX patients (from 37 LuTX centers), propensity matched to 106 controls without previous intrathoracic surgery (from 67 LuTX centers). This UNOS analysis identified a significantly increased risk of death (HR: 1.72; CI: 1.13-2.6; \( p = 0.01 \)) after LVRS+LuTX, which was
surprisingly not associated with the total number of LuTX (HR: 0.99) or the total number of LVRS+LuTX (HR: 0.99) of individual centers. Furthermore, the observed median survival was significantly worse in LVRS patients in comparison to matched controls (3.4 vs. 6.5; \( p = 0.038 \)).

The present study has several limitations. First, no donor specific characteristics apart from ischemic times of the donor lungs were taken into consideration. Secondly, there is substantial heterogeneity in how LVRS was performed. LVRS nowadays is routinely performed by a bilateral video-thoracoscopic approach and we can hypothesize that such a minimally invasive approach would have a lesser associated risk in a latter LuTX. In this cohort, sternotomy, thoracotomy, VATS, pleurectomy, pleurodesis and pleural tenting were in use and inevitably lead to pleural adhesions, albeit to different extent. By the sample size of 26 LVRS patients, this cannot be sufficiently considered. A similar limitation applies to different ELVR approaches (valves, coils, foam, vapor) having a different risk profile (pneumonia, exacerbation and pneumothorax) (27) and suggesting that their impact on a later LuTX may differ. A possible observer bias must be addressed with regards to the microbiological cultures. Although recipient bronchi were all sampled during LuTX, patients who underwent previous ELVR had supposedly more bronchoscopies and therefore more samples taken before transplant.

Most patients had LVR before being listed for transplantation \( (n = 78) \). “Bridging to LuTX” only took place in 8 patients who were already on the waiting list. Waiting time for LuTX was comparable throughout groups as presented in Table 1 (LVRS 180 days vs. 203 days in controls; ELVR 156 vs. 176 days in controls).

Additionally, critically ill patients who underwent LVR and were not later referred to LuTX (because of improvement, complications, or clinical misjudgment) were not considered. Hence, this study cannot predict the impact of LVR as an alternative to LuTX. It did not account for functional improvements while waiting, nor for changes in LS scores and impact on waiting times. The crucial question about QOL, functional/survival benefits, and timing of LVR before LuTX cannot be answered and the authors recommend further prospective investigation to answer it.

**CONCLUSION**

This study clearly demonstrates that patients who underwent previous surgical or endoscopic LVR can safely be considered for later LuTX. Although a marginally increased risk of specific complications and differences in airway colonization after LuTX were observed, short- and long-term survival was very good.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the ethics committee of the Medical Faculty of the University of Duisburg-Essen (21-9856-BO). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

**AUTHOR CONTRIBUTIONS**

All authors meet ICMJE criteria as they contributed substantially to this study. Conception: AS. Data collection: AS, CH, PB, JV, SS and CV. Data analysis and interpretation: AS, LC, CH, KH and CA. Drafting of the article: AS and CA. Critical revision of the article: LC, DV, KH, CA, MK and PJ. Final approval: AS, LC, CH, PB, JV, SS, DV, KH, CA, CV, MK and PJ.

**CONFLICT OF INTEREST**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**ACKNOWLEDGMENTS**

The authors wish to express their gratitude to the nurses, coordinators, assistants, anesthesiologists, intensive care physicians, pneumologists and surgeons involved in the programs of the participating centers. In particular, following persons are thanked for their commitment and their expert advice: Vasiliki Bessa, Kaid Darwiche, Christian Taube, Stephane Collaud, Achim Koch, Anna Frick, Alberto Benazzo, Nikolaus Pizanis. We acknowledge financial support by the Open Access Publication Fund of the University of Duisburg-Essen.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontierspartnerships.org/articles/10.3389/ti.2022.10048/full#supplementary-material
REFERENCES

1. van Agteren JE, Carson KV, Tiong LU, Smith BJ. Lung Volume Reduction Surgery for Diffuse Emphyema. Cochrane Database Syst Rev (2016) 10: CD001001. doi:10.1002/14651858.CD001001.pub3

2. Singer L, Singer J. Quality of Life in Lung Transplantation. Semin Respir Crit Care Med (2013) 34:421–30. doi:10.1055/s-0033-1348470

3. Criner GJ, Cordova F, Sternberg AL, Martinez FJ. The National Emphysema Treatment Program Interventions. Am J Respir Crit Care Med (2011) 184:881–93. doi:10.1164/rccm.201103-0455ci

4. Naunheim KS, Wood DE, Mohsenifar Z, DeCamp MM, et al. Long-term Follow-Up of Patients Receiving Lung Volume-Reduction Surgery versus Medical Therapy for Severe Emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg (2006) 82:431–43. doi:10.1016/j.athoracsur.2006.05.069

5. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, et al. A Randomized Trial Comparing Lung-Volume-Reduction Surgery with Medical Therapy for Severe Emphysema. N Engl J Med (2003) 348:2059–73. doi:10.1056/NEJMoa030287

6. Gompelmann D, Eberhardt R, Herth FJF. Endoscopic Lung Volume Reduction. A European Perspective. Ann ATS (2013) 10:657–66. doi:10.1513/annalsats.201301-003fr

7. Darwiche K, Aigner C. Clinical Management of Lung Volume Reduction in End Stage Emphysema Patients. J Thorac Dis (2018) 10:S2732–S2737. doi:10.21037/jtd.2018.02.69

8. Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A Consensus Document for the Selection of Lung Transplant Candidates: 2014: An Update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant (2015) 34:1–15. doi:10.1016/j.healun.2014.06.014

9. Darwiche K, Kapfä-Wissel R, Eisenmann S, Aigner C, Welter S, Zarogoulidis P, et al. Bronchoscopic Lung Volume Reduction with Endobronchial Valves in Low-FEV1 Patients. Respiratio (2016) 92:414–9. doi:10.1159/000452629

10. Trudzinski FC, Höink AJ, Leppert D, Fähndrich S, Willens H, Graeter TP, et al. Endoscopic Lung Volume Reduction Using Endobronchial Valves in Patients with Severe Emphysema and Very Low FEV1. Respiratio (2016) 92:258–65. doi:10.1159/000448761

11. Slama A, Taube C, Kämmer M, Aigner C. Lung Volume Reduction Followed by Lung Transplantation: Considerations on Selection Criteria and Outcome. J Thorac Dis (2018) 10:S3366–S3375. doi:10.21037/jtd.2018.06.144

12. Krishnan A, Chidi A, Merlo CA, Shah PD, Ha J, Higgins RSD, et al. Lung Volume Reduction Surgery Prior to Lung Transplantation: A Propensity-Matched Analysis. Ann Thorac Surg (2021) 113(2):491–7. doi:10.1016/j.athoracsur.2021.02.009

13. Backhus L, Sargent J, Cheng A, Zeliada S, Wood D, Mulligan M. Outcomes in Lung Transplantation after Previous Lung Volume Reduction Surgery in a Contemporary Cohort. J Thorac Cardiovasc Surg (2014) 147:1678–83. doi:10.1016/j.jtcvs.2014.01.045

14. Burns KEA, Keenan RJ, Gergich WF, Manzetti JD, Zenati MA. Outcomes of Lung Volume Reduction Surgery Followed by Lung Transplantation: A Matched Cohort Study. Ann Thorac Surg (2002) 73:1587–93. doi:10.1016/s0003-4975(02)0499-9

15. Shigemura N, Gilbert S, Bhama JK, Crespo MM, Zaldonis D, Pilewski JM, et al. Lung Transplantation after Lung Volume Reduction Surgery. Transplantation (2013) 96:421–5. doi:10.1097/TP.0b013e31829535ac

16. Wisser W, Deviatko E, Simon-Kuplik N, Senbadkavci O, Huber ER, Wolner E, et al. Lung Transplantation Following Lung Volume Reduction Surgery. J Heart Lung Transplant (2000) 19:480–7. doi:10.1053/jlt.2000.00085-I

17. Inci I, Iskender I, Ehrsam J, Caviezel C, Hillinger S, Opitz I, et al. Previous Lung Volume Reduction Surgery Does Not Negatively Affect Survival after Lung Transplantation?. Eur J Cardiothorac Surg (2018) 53:596–602. doi:10.1093/ejcts/ezx318

18. Fuehner T, Clajus C, Fuge J, Jonigk D, Welte T, Haverich A, et al. Lung Transplantation after Endoscopic Lung Volume Reduction. Respiration (2015) 90:243–50. doi:10.1159/000434685

19. Sarmand N, Gompelmann D, Kontogianni K, Polke M, Herth FJ, Eberhardt R. New Bacterial Growth in Bronchial Secretions after Bronchoscopic Valve Implantation. Int J Chron Obstruct Pulmon Dis (2018) 13:565–70. doi:10.2147/ijcopd.s148196

20. Jacus SM, King G, Porro G. Cem: Software for Coarsened Exact Matching. J Stat Softw (2009) 30:1–27. doi:10.18637/jss.v030.i09

21. King G, Nielsen R. Why Propensity Scores Should Not Be Used for Matching. Polit Anal (2019) 27:435–54. doi:10.1017/paan.2019.11

22. Altun GT, Arslantaş MK, Çinel İ. Primary Graft Dysfunction after Lung Transplantation. Turk J Anaesthesiol Reanim (2015) 43:418–20. doi:10.5152/TJA.R.2015.16443

23. Borders CF, Suzuki Y, Laskey J, Schaufler C, Mallem D, Lee J, et al. Massive Donor Transfusion Potentially Increases Recipient Mortality after Lung Transplantation. J Thorac Cardiovasc Surg (2017) 153:1197–203. doi:10.1016/j.jtcvs.2016.12.006

24. Weber D, Cottini SR, Locher P, Wenger U, Stehberger PA, Fasshauer M, et al. Association of Intraoperative Transfusion of Blood Products with Mortality in Lung Transplant Recipients. Perioper Med (2013) 2:20. doi:10.1186/2037-0525-2-20

25. Paglicci L, Borgo V, Lanzarone N, Fabbiani M, Cassol C, Cusi MG, et al. Incidence and Risk Factors for Respiratory Tract Bacterial Colonization and Infection in Lung Transplant Recipients. Eur J Clin Microbiol Infect Dis (2021) 40(6):1271–82. doi:10.1007/s10096-021-04153-1

26. Fruchtner O, Rosengarten D, Goldberg E, Ben-Zvi H, Tor R, Kramer MR. Airway Bacterial Colonization and Serum C-Reactive Protein Are Associated with Chronic Obstructive Pulmonary Disease Exacerbation Following Bronchoscopic Lung Volume Reduction. Clin Respir J (2016) 10:239–45. doi:10.1111/crj.12211

27. Ramaswamy AA, Puchalski J. Bronchoscopic Lung Volume Reduction: Recent Updates. J Thorac Dis (2018) 10:2519–27. doi:10.21037/jtd.2018.02.72

Copyright © 2022 Slama, Ceulemans, Hedderich, Boehm, Van Slambrouck, Schwarz, Vanderwelde, Kamler, Jaksch, Van Raemdonck, Hoetzenecker and Aigner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.